SEC Filings

Filing links are provided when reliable SEC filing data is available.

Recent Filings

Form	Filing Date	Accepted	Document
N-PX	Aug 25, 2026	Aug 25, 2026	View filing
4	Aug 12, 2026	Aug 12, 2026	View filing
3	Aug 12, 2026	Aug 12, 2026	View filing
4	Aug 7, 2026	Aug 7, 2026	View filing
6-K	Aug 6, 2026	Aug 6, 2026	View filing
3	Aug 4, 2026	Aug 4, 2026	View filing
6-K	Jul 30, 2026	Jul 30, 2026	View filing
6-K	Jul 30, 2026	Jul 30, 2026	View filing
13F-HR	Jul 28, 2026	Jul 28, 2026	View filing
6-K	Jul 27, 2026	Jul 27, 2026	View filing
SC 13G/A	Jul 22, 2026	Jul 22, 2026	View filing
6-K	Jul 17, 2026	Jul 17, 2026	View filing
6-K	Jul 7, 2026	Jul 7, 2026	View filing
11-K	Jun 30, 2026	Jun 30, 2026	View filing
11-K	Jun 30, 2026	Jun 30, 2026	View filing
NT 11-K	Jun 30, 2026	Jun 30, 2026	View filing
NT 11-K	Jun 30, 2026	Jun 30, 2026	View filing
6-K	Jun 24, 2026	Jun 24, 2026	View filing
6-K	Jun 22, 2026	Jun 22, 2026	View filing
6-K	Jun 12, 2026	Jun 12, 2026	View filing
6-K	Jun 8, 2026	Jun 8, 2026	View filing
SD	May 28, 2026	May 28, 2026	View filing
6-K	May 27, 2026	May 27, 2026	View filing
13F-HR	May 7, 2026	May 7, 2026	View filing
SC 13G	May 6, 2026	May 6, 2026	View filing
6-K	May 5, 2026	May 5, 2026	View filing
6-K	Apr 29, 2026	Apr 29, 2026	View filing
6-K	Apr 27, 2026	Apr 27, 2026	View filing
6-K	Apr 23, 2026	Apr 23, 2026	View filing
6-K	Apr 15, 2026	Apr 15, 2026	View filing

About Sanofi

Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.

Paris, IF

76,493 employees

www.sanofi.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Belén Garijo López

View full financials